MIAMI, July 9, 2024
/PRNewswire/ -- Thylacine Biotherapeutics is pleased to announce
its first-place award in the prestigious Medical Threat Reduction
Challenge, sponsored by Advanced Technology International (ATI) and
the Medical CBRN Defense Consortium (MCDC). Following a competitive
evaluation of more than three hundred submissions, Thylacine
emerged as one of 14 finalists selected to present at the
TechConnect World conference in Washington DC. Thylacine presented before a
panel of judges with vast experience from time working with medical
countermeasure development within both Health and Human Services
and the Department of Defense.
Thylacine showcased its groundbreaking rapid-response,
broad-spectrum antiviral platform, developed at Columbia University by Drs. Matteo Porotto and
Anne Moscona. This innovative
platform may be used to target a diverse array of viruses,
including SARS-CoV-2; influenza, RSV, and high-consequence
biothreats such as Ebola and Nipah.
"In a highly competitive field, Thylacine Bio's technology stood
apart in its potential to protect the warfighter from a broad array
of viral threats," remarked Dr. Mike
Stebbins, Senior Vice President for ATI, lead for their
Medical and Threat Countermeasures Division and Executive Director
of MCDC.
Thylacine's lead candidate, THY-01, has demonstrated efficacy
against various coronaviruses, including SARS-CoV-2, SARS, and
MERS. The platform's versatility allows for rapid adaptation to new
viral threats using a proprietary toolkit approach, ensuring timely
response and effectiveness.
"Our platform represents a paradigm shift in antiviral
therapies," said Dr. Elma Hawkins,
Executive Chairwoman at Thylacine Biotherapeutics. "Designed to
address endemic infectious disease, and combat multiple viral
biothreats, our technology leverages novel lipopeptides that
effectively inhibit viral entry and block transmission."
Supported over 17 years with $31
million in NIH-sponsored research to Drs. Porotto and
Moscona, this platform is poised to transform global health
security with its ability to mitigate both endemic and emerging
viral threats.
About MCDC: The MCDC Consortium accelerates the
deployment of medical countermeasures for the US Department of
Defense, addressing critical pharmaceutical and diagnostic needs to
enhance the readiness of military personnel.
About Advanced Technology International: ATI, a
public-service nonprofit based in Summerville, S.C., builds and manages
collaborations that conduct research and development of new
technologies to solve our nation's most pressing challenges. Fueled
by a community of experts from industry, academia, and government,
ATI accelerates impact by using the power of collaboration to help
the federal government quickly acquire novel technologies.
About Thylacine Biotherapeutics: Thylacine
Biotherapeutics, headquartered in Miami,
FL is dedicated to pioneering antiviral therapies to combat
a wide range of global medical threats.
Contact: Daniel Graifman, President
dgraifman@thylacine-bio.com, www.thylacine-bio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/thylacine-biotherapeutics-earns-top-honor-in-medical-threat-reduction-challenge-302191267.html
SOURCE Thylacine Biotherapeutics Inc.